Episode

JAMA Neurology : Gefurulimab and Generalized Myasthenia Gravis

Podcast
JAMA Network
Published
Jul 27, 2026
Duration seconds
1002
Processing state
not_requested
Canonical source
https://edhub.ama-assn.org/jn-learning/audio-player/10.1001/jamaneurol.2026.2687
Audio
http://traffic.libsyn.com/jamaneurologyauthorinterviews/Gefurulimab_and_Generalized_Myasthenia_Gravis_1.mp3
JSON
/v1/public/podcasts/jama-network-1057758/episodes/jama-neurology-gefurulimab-and-generalized-myasthenia-gravis
Markdown
/podcast/jama-network-1057758/jama-neurology-gefurulimab-and-generalized-myasthenia-gravis.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/jama-network-1057758/episodes/jama-neurology-gefurulimab-and-generalized-myasthenia-gravis/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/jama-network-1057758/jama-neurology-gefurulimab-and-generalized-myasthenia-gravis.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Interview with Kelly G. Gwathmey, MD, author of Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial. Hosted by Cynthia E. Armand, MD. Related Content: Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis Gefurulimab—The First Effective Nanobody in Myasthenia Gravis Therapy